Company Overview of CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as a biotechnology company that develops antibody therapeutics. It offers Probody therapeutics (immunotherapies and antibody drug conjugate therapies) for the treatment of cancer. CytomX Therapeutics, Inc. has strategic partnerships with Pfizer Inc., ImmunoGen, Inc., and Bristol-Myers Squibb. The company was founded in 2008 and is based in South San Francisco, California.
343 Oyster Point Boulevard
South San Francisco, CA 94080-1913
Founded in 2008
Key Executives for CytomX Therapeutics, Inc.
Chief Executive Officer and Director
Founder and Member of Scientific Advisory Board
Consulting Chief Financial Officer
Chief Scientific Officer and Head of Research & Early Development
Compensation as of Fiscal Year 2014.
CytomX Therapeutics, Inc. Key Developments
CytomX Appoints Immuno-Oncology Leader Rachel Humphrey, M.D., to Board of Directors
Mar 19 15
CytomX announced the appointment of Rachel Humphrey, M.D., to its board of directors. Dr. Humphrey previously led immuno-oncology at AstraZeneca and prior to that was responsible for the clinical development of both Yervoy® (ipilmumab) at Bristol-Myers Squibb and Nexavar® (sorafenib) at Bayer. Dr. Humphrey recently served as senior vice president and head of immuno-oncology at AstraZeneca Pharmaceuticals. In this capacity, she was responsible for leading the therapeutic area's strategy and oversaw all aspects of the development of its PD-L1 inhibitor (MEDI4736), tremelimumab and the combination.
CytomX Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:00 PM
Feb 26 15
CytomX Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:00 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Sean A. McCarthy, Chief Executive Officer and Director.
CytomX Therapeutics Announces Executive Appointments
Jan 5 15
CytomX Therapeutics announced that it has appointed W. Michael Kavanaugh, M.D., as chief scientific officer and head of research and early development. In addition, the company has appointed Sridhar Viswanathan, Ph.D., as vice president of process sciences and manufacturing sciences and Danielle Olander as vice president of human resources. Prior to joining the company, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics. Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company's therapeutic pipeline. Dr. Viswanathan joins the company from Perseid Therapeutics, where he served as vice president of process development and manufacturing operations. In this capacity, he was responsible for all internal process development and external manufacturing operations at contract manufacturing organizations for advancing CTLA4-Ig Fc fusion products for autoimmune disease and organ transplant rejection. Ms. Olander joined the company from Portola Pharmaceuticals where she served as the senior director of human resources management, leading all facets of human resources. This included the development of effective strategies that enabled Portola to thrive through periods of change, as well as supported short and long-term business objectives.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 11, 2015
December 22, 2014